In the realm of early-stage TNBC treatment, the PD-1 inhibitor KEYTRUDA (pembrolizumab) has emerged as a pivotal component. Administered in conjunction with neoadjuvant chemotherapy and continued as adjuvant monotherapy, KEYTRUDA has showcased promising results. Particularly in PD-L1-positive patients with a CPS ≥10, it is utilized alongside chemotherapy for locally recurrent or metastatic disease. The landscape of targeted therapies is also evolving, offering hope to patients with BRCA mutations. PARP inhibitors like LYNPARZA (olaparib) and TALZENNA (talazoparib) are designed to target defective DNA repair pathways, presenting new avenues for treatment.
Additionally, TRODELVY (sacituzumab govitecan), an antibody-drug conjugate targeting TROP-2, has received approval for relapsed or treatment-resistant metastatic TNBC cases. While TECENTRIQ (atezolizumab) faced setbacks in the U.S. market, it remains accessible in Europe and Japan. The Triple-Negative Breast Cancer Market Insights report by DelveInsight sheds light on the expanding landscape of TNBC treatment, with emerging therapies like DATROWAY, PADCEV, BNT327/PM8002, and others poised to drive market growth. Companies like AstraZeneca, Daiichi Sankyo, and Pfizer are at the forefront of developing innovative treatments for TNBC, offering hope to patients and healthcare providers alike.
Read more from finance.yahoo.com